131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.
Nucl Med Commun., Dec;33(12):1225-31 (2012)
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.
Clin. Cancer Res., Oct;18(20):5752-60 (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica., Nov;97(11):1736-42 (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood., Apr;119(17):3940-50 (2012)
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Clin. Cancer Res., Dec;17(23):7373-82 (2011)
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Br. J. Haematol., Oct;155(2):182-9 (2011)
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
J. Clin. Oncol., Aug;29(22):3023-9 (2011)
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Blood., Jul;118(3):703-11 (2011)
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Oct;17(10):1537-45 (2011)
â¹â°Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Blood., Jul;118(4):1132-9 (2011)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
J. Clin. Oncol., Mar;29(9):1190-7 (2011)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.
Biol. Blood Marrow Transplant., Jun;17(6):908-15 (2011)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Blood., Nov;116(20):4231-9 (2010)
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Biol. Blood Marrow Transplant., Mar;17(3):341-50 (2011)
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Bioconjug. Chem., Jul;21(7):1225-38 (2010)
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignan
Biol. Blood Marrow Transplant., Aug;16(8):1037-69 (2010)
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Leuk. Lymphoma., Aug;51(8):1523-9 (2010)
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.
Biol. Blood Marrow Transplant., Oct;16(10):1382-7 (2010)
Pretargeted radioimmunotherapy for hematologic and other malignancies.
Cancer Biother. Radiopharm., Apr;25(2):125-42 (2010)